Novo Nordisk Navigates Tariff Threats, Legal Battles, and Regulatory Wins

Novo Nordisk navigates US generics tariffs, secures Wegovy approvals in India and EU, and launches a lawsuit against Eli Lilly amid stock volatility.

Novo Nordisk finds itself juggling an unusually complex set of forces this summer. The Danish pharmaceutical giant has secured two major regulatory approvals in quick succession, launched a legal offensive against archrival Eli Lilly, and is now contending with a new US tariff timeline that has rattled the broader pharma sector. The stock closed Thursday at €42.27, up 0.43 percent on the day, but down 3.80 percent on the week — a reflection of the crosscurrents buffeting the company.

Tariff Clock Starts Ticking

The most significant macro headwind arrived when President Donald Trump unveiled a phased tariff plan for imported generic drugs. Under the proposal, no tariffs will apply for the first two years starting August 1, followed by a 100 percent rate in August 2028 and a jump to 200 percent a year later. Trump framed the escalation as a penalty for manufacturers that fail to build production capacity inside the US within that window.

While the new tariffs target generics rather than patented medicines, they compound an already fraught trade environment. In April, Trump imposed a 100 percent tariff on patented pharmaceutical products under Section 232, granting major manufacturers a 120-day grace period. Generics, biosimilars, and related active ingredients were excluded from that earlier measure.

Novo Nordisk has already secured some protection. It is among more than a dozen large drugmakers — including Eli Lilly and Pfizer — that struck pricing agreements with the Trump administration. In exchange for committing to lower US prices tied to cheaper overseas rates, these companies received a three-year exemption from tariffs on patented drugs.

The announcement of the new generics tariff schedule sent shockwaves through the sector. Sandoz, the Swiss generics specialist, lost as much as 4.2 percent in Zurich trading. Novo Nordisk has been repeatedly cited among the pharma names under pressure this week.

Regulatory Wins Offer a Counterweight

Amid the tariff noise, Novo Nordisk notched two significant regulatory victories in the second half of July. India’s drug regulator, the CDSCO, approved the 2.4-mg injectable dose of Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Semaglutide becomes the first and only GLP-1 therapy authorized in India for this specific liver condition. The approval was backed by Phase 3 data from the ESSENCE study, which showed steatohepatitis resolution in 63 percent of patients versus 34 percent in the placebo group.

Just days earlier, on July 15, the European Commission approved the oral Wegovy tablet — the first GLP-1 therapy in pill form to receive EU authorization. Since the start of 2026, more than three million prescriptions for the oral formulation have been written, signaling robust early uptake.

Legal Offensive Against Lilly Backfires — For Now

Novo Nordisk has also taken the fight to its biggest rival in court. The company filed a lawsuit in federal court in New Jersey accusing Eli Lilly of misleading advertising for its obesity drug Zepbound and diabetes treatment Mounjaro. The complaint alleges that Lilly compares its highest approved doses against lower doses of Novo’s own Wegovy and Ozempic, while failing to disclose its own higher-strength formulations.

The lawsuit was intended as an offensive move to level the competitive playing field. But the market has interpreted it differently — as a sign of mounting pressure in the GLP-1 category rather than a clear competitive victory. The legal battle adds another layer of uncertainty to a stock that has already lost significant ground.

Analyst Skepticism Persists

The regulatory successes have done little to shift analyst sentiment. Morningstar lowered its fair value estimate for the stock from $54 to $48, citing higher cost-of-capital assumptions and a weaker assessment of the company’s capital allocation. Zacks Investment Research downgraded Novo Nordisk to "Strong Sell." Citi maintained its neutral rating on the B-shares while modestly raising its price target, suggesting limited upside. Of the 24 analysts covering the stock, the majority still recommend a hold.

Cyber Incident Adds to the Narrative

Investor sentiment has also been weighed down by a cyberattack whose details emerged on July 22. The group FulcrumSec stole approximately 1.3 terabytes of data in June, including pseudonymized clinical trial data and contact information for healthcare professionals. Production was unaffected — Novo Nordisk’s largest insulin plant in Kalundborg continued operating without interruption, underscoring the separation between its IT and manufacturing systems.

Buyback Program Rolls On

Despite the headwinds, Novo Nordisk has continued its capital return program. Since February 4, 2026, the company has repurchased nearly 25 million B-shares at an average price of 274.58 Danish kroner, representing a transaction value of roughly 6.85 billion kroner. Novo now holds 42.1 million of its own B-shares, equivalent to 0.9 percent of share capital. The current tranche is part of a larger buyback program of up to 15 billion kroner, which runs through February 2027.

What’s Ahead

The stock currently trades at €42.27, roughly 31 percent below its 52-week high of €60.95 and about 5 percent above its 50-day moving average of €40.27. The relative strength index of 53.5 points to neutral technical conditions with no clear directional bias.

Two catalysts loom. The US Food and Drug Administration is expected to rule this month on Mim8 (Denecimig), Novo’s next-generation hemophilia A treatment. Then on August 5, the company will report first-half earnings — a critical test of whether the rapid adoption of oral Wegovy can offset pricing pressure in the US market. Novo Nordisk is defending its position on two fronts simultaneously: through pricing agreements in Washington and a courtroom battle against its fiercest rival. The next quarterly report will show whether that strategy is holding.